Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting

This study demonstrates that engineering a novel anti-FAP single-domain antibody (VHH) into monomeric, dimeric, and Fc-fusion formats allows for the tuning of pharmacokinetic properties to optimize tumor uptake, retention, and radiation dosimetry for improved cancer theranostics targeting fibroblast activation protein.

The Gist

The Big Picture: Finding a Better Key for a Broken Lock

Imagine cancer isn't just a single bad cell, but a whole neighborhood of bad cells (the tumor) surrounded by a supportive crew of "construction workers" called Cancer-Associated Fibroblasts (CAFs). These workers build the scaffolding that helps the tumor grow and hide from the immune system.

On the surface of these construction workers is a specific "badge" called Fibroblast Activation Protein (FAP). If we can find a way to spot this badge, we can see the tumor on a scan (diagnostics) or deliver a radioactive "bomb" to destroy it (therapy). This is called theranostics.

The Problem: The Old Keys Were Too Flimsy

Scientists have been using small chemical keys (called FAPIs) to find this badge.

• The Analogy: Imagine trying to pick a lock with a tiny, flimsy paperclip. It fits in the keyhole, but it's so small and light that it slips out of the lock very quickly.
• The Result: These small keys get into the tumor fast, but they also wash out of the body fast. They don't stick around long enough to do much damage or give a clear picture.

The New Solution: The Camel's Super-Tool

The researchers decided to try a different approach. Instead of a tiny paperclip, they used a Single-Domain Antibody (VHH).

• The Analogy: Think of a VHH as a Lego brick made from a camel's immune system. It's tiny (much smaller than a full human antibody), very sturdy, and has a unique shape that can reach into tight spots that other keys can't.

They found a specific Lego brick (named F7) that fits the FAP badge perfectly. But they didn't stop there. They wanted to see if changing the shape and size of this Lego brick would make it stick better.

The Experiment: Three Different Versions of the Key

The team built three different versions of their F7 Lego brick to see which one worked best:

1. The Solo Brick (F7 Monomer):

   • What it is: Just one single F7 brick.
   • The Analogy: A single person running to the tumor.
   • Result: It ran there very fast (faster than the old paperclip keys!) and stuck for a little while, but it was still a bit too light to stay for a long time.

2. The Double-Handed Brick (F7 Dimer):

   • What it is: Two F7 bricks tied together with a string.
   • The Analogy: Two people holding hands. If one slips, the other holds on.
   • Result: This was a huge improvement. Because it had two "hands" to grab the badge, it held on much tighter. It cleared out of the blood quickly but stayed stuck in the tumor, creating a very clear picture with less background noise.

3. The Heavy Backpack (F7-Fc Fusion):

   • What it is: The F7 brick attached to a large "backpack" (an Fc fragment, which is part of a human antibody).
   • The Analogy: A person wearing a heavy backpack. They move slower than the solo runner, but once they get to the destination, they are too heavy to be blown away by the wind.
   • Result: This was the champion. It took a little longer to get to the tumor, but once it arrived, it stayed there for days. It allowed the scientists to take pictures of the tumor over a period of 6 days (144 hours), which is impossible with the small keys.

The Results: Why This Matters

The researchers tested these keys in mice with prostate cancer. Here is what they found:

• Speed vs. Stickiness: The small, single brick (F7) was the fastest, but the heavy backpack (F7-Fc) was the stickiest.
• Clearing the Clutter: The body is good at cleaning up small things (like the solo brick) through the kidneys. The heavy backpack stayed in the blood longer, giving it more time to find the tumor.
• The "Golden Ratio": The heavy backpack (F7-Fc) delivered the highest amount of radiation to the tumor while keeping the dose to healthy organs (like the liver and kidneys) relatively low.
• Long-Term Vision: Because the heavy backpack stayed in the tumor for so long, doctors could take "time-lapse" photos of the cancer, watching how the treatment worked over several days.

The Takeaway

This study is like a lesson in engineering. The researchers proved that you don't just need a "good" key; you need the right size key for the job.

• If you need speed, use the small key.
• If you need to hold on tight and stay for a long time (for better imaging or therapy), use the heavy, double-handed version.

By tuning the size and shape of these camel-derived antibodies, the team created a much better tool for seeing and treating cancer, potentially leading to more effective treatments with fewer side effects for patients in the future.

Technical Summary

1. Problem Statement

Fibroblast Activation Protein (FAP) is a cell-surface serine protease highly expressed on Cancer-Associated Fibroblasts (CAFs) within the tumor microenvironment (TME) of most solid tumors, making it an ideal target for theranostics (combined therapy and diagnostics). However, current targeting strategies face limitations:

• Small-Molecule Inhibitors (FAPIs): While widely used, FAPIs have low nanomolar affinity due to limited molecular contacts with FAP. They exhibit rapid tumor washout and poor retention, which limits their efficacy for radiotherapy and reduces tumor-to-background ratios in imaging.
• Antibody Limitations: Full-length antibodies have long circulation half-lives, leading to high background signal and delayed imaging windows.
• The Gap: There is a need for targeting vectors that combine the rapid tumor penetration of small molecules with the high affinity and retention of biologics, while offering tunable pharmacokinetics (PK) through engineering.

2. Methodology

The study employed a multi-stage approach to identify, engineer, and evaluate novel FAP-targeting vectors:

• VHH Discovery and Affinity Maturation:

  • A novel anti-FAP Variable Heavy-Heavy domain (VHH, or nanobody) was identified from a naïve camelid phage display library.
  • Lead Selection: Initial clone NbC (70 nM affinity) was selected.
  • Affinity Maturation: Site-specific mutagenesis was performed on CDR1 and CDR3 regions, followed by two rounds of biopanning against recombinant human FAP. This yielded a lead clone, F7, with a significantly improved affinity ($K_D \approx 9$ nM) and high bacterial expression yield (>30 mg/L).

• Scaffold Engineering (Valency and Size Tuning):
  To investigate how molecular weight and valency affect biodistribution, F7 was engineered into three distinct formats:

  1. Monomer (F7): ~15 kDa, monovalent.
  2. Tethered Dimer (F7D): ~28 kDa, bivalent homodimer linked by a $(G_4S)_5$ linker.
  3. Fc-Fusion (F7-Fc): ~80 kDa, bivalent fusion with a human IgG1 Fc domain.

• In Vitro Characterization:

  • Binding Affinity: Measured via Biolayer Interferometry (BLI).
  • Specificity: Validated via ELISA (against FAP vs. DPPIV) and Flow Cytometry on FAP-positive (CWR-R1FAP) vs. FAP-negative (CWR-R1) prostate cancer cell lines.

• In Vivo Imaging and Biodistribution:

  • Models: Athymic nude mice bearing subcutaneous CWR-R1FAP (FAP+) and CWR-R1 (FAP-) xenografts.
  • Radiolabeling: Constructs were labeled with $^{64}$Cu (for short-term imaging) and $^{89}$Zr (for long-term longitudinal imaging) using NOTA chelators.
  • Imaging: MicroPET/CT scans were performed at various timepoints (1h to 144h).
  • Comparators: F7 monomer was directly compared against the clinical small-molecule tracer $^{68}$Ga-FAPI-46.
  • Dosimetry: Absorbed dose calculations were performed using the RAPID Monte Carlo platform.
  • Histology: Ex vivo autoradiography (iQID) and H&E staining were used to confirm tracer localization and tissue architecture.

3. Key Contributions

• Discovery of F7: Identification of a high-affinity, high-yield anti-FAP VHH (F7) that outperforms initial leads.
• Systematic Engineering: Demonstration that tuning the valency (monomer vs. dimer) and molecular weight (15kDa vs. 80kDa) of a single VHH scaffold allows for precise control over pharmacokinetics.
• Superiority over Small Molecules: Direct evidence that a protein-based VHH can achieve higher tumor uptake and retention than the gold-standard small-molecule FAPI-46.
• Longitudinal Imaging Capability: Establishment of an Fc-fusion format (F7-Fc) capable of sustained tumor retention for over 144 hours, enabling delayed imaging and potential therapeutic applications.

4. Key Results

In Vitro Binding

• Affinity: The monomer F7 had a $K_D$ of 9 nM. Bivalent engineering drastically improved affinity: F7D ($K_D = 29$ pM) and F7-Fc ($K_D = 38$ pM).
• Kinetics: The bivalent constructs exhibited significantly slower dissociation rates ($k_d$) compared to the monomer, driving the high affinity.
• Specificity: All constructs showed specific binding to FAP-positive cells with minimal cross-reactivity to FAP-negative cells or the homologous enzyme DPPIV.

In Vivo Imaging and Biodistribution

• F7 (Monomer) vs. FAPI-46:

  • F7 showed 2-fold higher tumor uptake than FAPI-46 at 1 hour post-injection (1.1% ID/g vs. 0.58% ID/g).
  • F7 maintained high uptake at 4 hours (0.92% ID/g) while FAPI-46 washed out rapidly.
  • F7 cleared rapidly from blood and kidneys, similar to small molecules, but with superior tumor retention.

• F7D (Dimer):

  • Rapid tumor localization with sustained retention.
  • Tumor uptake remained high at 24 hours (1.27% ID/g).
  • Tumor-to-Blood Ratio: Improved significantly over time (4-fold lower blood uptake at 24h compared to tumor), indicating effective clearance from circulation while retaining in the tumor.
  • Clearance: Primarily renal (high kidney uptake), typical for low-molecular-weight proteins.

• F7-Fc (Fc-Fusion):

  • Highest Tumor Uptake: Achieved 7.5% ID/g at 4h, peaking at 15.23% ID/g at 24h, and maintaining 10.13% ID/g at 144h.
  • Clearance Profile: Slower blood clearance (typical of Fc-containing antibodies) but significantly reduced renal uptake compared to F7D (due to Fc-mediated recycling and larger size).
  • Liver Uptake: Higher liver accumulation than F7D, consistent with Fc receptor interactions and size, but still favorable for imaging.
  • Longitudinal Imaging: Using $^{89}$Zr, the construct allowed clear imaging up to 144 hours, with tumor signal remaining robust while background cleared.

Dosimetry and Safety

• Radiation Dose: Calculations for $^{89}$Zr-F7-Fc showed tumors received significantly higher absorbed doses than normal tissues.
• Selectivity: Tumor-to-organ dose ratios exceeded 4:1 for bone and >2:1 for liver and kidney, suggesting a high therapeutic index for potential radiotherapeutic applications.
• Histology: iQID autoradiography confirmed persistent tracer localization within the tumor tissue at 144 hours, correlating with viable tumor regions.

5. Significance

This study establishes a modular platform for FAP-targeted theranostics. By demonstrating that a single VHH sequence (F7) can be engineered into different formats to suit specific clinical needs, the authors provide a solution to the limitations of current FAP tracers:

1. Rapid Imaging: The monomer (F7) offers a "small-molecule-like" profile with superior uptake, suitable for same-day imaging.
2. High-Contrast Imaging: The dimer (F7D) offers an optimal balance of rapid clearance and high retention, maximizing tumor-to-background ratios within 24 hours.
3. Therapeutic Potential: The Fc-fusion (F7-Fc) provides prolonged retention and high tumor dose delivery, making it a prime candidate for radioimmunotherapy (RIT) or long-term imaging.

The findings suggest that tuning valency and molecular weight is a critical strategy for optimizing antibody-based targeting vectors, potentially overcoming the washout issues inherent to small-molecule FAPIs and the slow clearance of full-length antibodies. This paves the way for more effective FAP-targeted cancer diagnostics and treatments.